Zuellig Pharma and Amgen Philippines on cardiovascular diseases
Health

Amgen and Zuellig Pharma on Cardiovascular Diseases

Prevention is better than cure – this is what we always hear especially from our family doctors. It’s wise advice because there are diseases which can be prevented from happening or can be managed with early detection. A regular check-up and assessment is a must. Keeping your overall health always in check can give you an idea of future risk factors and how you can avoid it from happening.

There are factors in order to predict and prevent health issues such as a heart attack and Zuellig Pharma Corporation in partnership with Amgen Philippines Inc is working on helping improve awareness of cardiovascular diseases (CVD) with educational initiatives to achieve the goal of changing the way the disease is managed and prevented.

Support from your family and friends is one of the keys to helping patients impacted by health challenges. When equipped with more information about cardiovascular diseases such as hyperlipidemia, family members can help patients take action to prevent health risks and overcome their conditions better.

In the Philippines, there are over 130,000 deaths related to Cardiovascular disease in 2016 CVD is a complex disease with many risk factors that affects how it develops. One such risk is dyslipidemia, which occurs when one has abnormal levels of lipids in the blood. Lipids, or fats, are essential in providing energy to the cells while cholesterol is vital in the production of hormones and bile acids for healthy digestion.

Zuellig Pharma and Amgen Philippines on cardiovascular diseases


There are two kinds of cholesterol in the body: “Bad” cholesterol and ‘good” cholesterol. Elevated bad cholesterol, also known as low-density lipoprotein (LDL-C), in the blood increases a person’s risk of developing atherosclerotic plaque deposits which can block the arteries and lead to a heart attack or stroke. Lowering LDL-C also lowers a person’s chances of developing CVD.

The standard treatment for lowering LDL-C are statins, but there are cases when statins are not enough. Having access to new and innovative treatments in the management of dyslipidemia can make a difference for patients who are not able to achieve their lipid goals with statin alone.

With the patient at the heart of what we do, Amgen Philippines Inc. and Zuellig Pharma Corporation are committed to improving the lives of patients struggling with dyslipidemia by helping them and their families to take the necessary action to prevent and manage their health risks.

Hits: 113

You may also like...

Leave a Reply